CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 152 enrolled
Drug / intervention
Trastuzumab deruxtecandrug
Likely dose
Trastuzumab deruxtecan 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04644237
NCT04644237Phase 2Completed
CompareCT.gov

A Phase 2, Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)

Daiichi Sankyo·interventional·Posted Nov 25, 2020·Updated Nov 21, 2025

In Brief

A Phase 2 clinical trial evaluating Trastuzumab deruxtecan for Non-Small Cell Lung Cancer. Completed, enrolled 152 participants across 50 sites in 10 countries.

Detailed Summary

This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell lung cancer (NSCLC) participants who had disease recurrence or progression during/after at least one regimen of prior anticancer therapy (second line or later) that must have contained a platinum-based chemotherapy drug.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesAustralia, Canada, France, Italy, Japan, Netherlands, South Korea, Spain, Taiwan, United States
CollaboratorsAstraZeneca

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedNov 25, 2020
Enrollment StartMar 19, 2021
Primary CompletionDec 23, 2022
Study CompletionAug 23, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.6 years ago

Interventions

Trastuzumab deruxtecandrug

Trastuzumab deruxtecan 100 mg will be provided as a sterile lyophilized powder and reconstituted with 5 mL water for injection (final concentration 20 mg/mL \[ie, 100 mg/5 mL\]). The study drug will be administered as an intravenous (IV) infusion over 30 to 90 min Q3W ± 2 days. The initial dose of study drug will be infused for 90 ± 10 min.